Article info
PDFEditorial commentary
Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis
- Correspondence to Dr Jeffrey Marc Gelfand, Department of Neurology, Division of Neuroimmunology and Glial Biology, University of California, San Francisco (UCSF), San Francisco CA 94158, California, USA; Jeffrey.Gelfand{at}ucsf.edu
Citation
Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis
Publication history
- Received February 25, 2021
- Revised March 1, 2021
- Accepted March 2, 2021
- First published March 30, 2021.
Online issue publication
March 30, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.